Skip to main content
SpringerLink
Log in
Book cover

Therapieresistenz unter Neuroleptikabehandlung pp 115–129Cite as

Die Bedeutung der verschiedenen Neuroleptikagruppen unter dem Aspekt von Neuroleptika-Nonresponse

  • Conference paper

Zusammenfassung

Während die Wirksamkeit der Neuroleptika in der Akutbehandlung schizophrener Erkrankungen durch die klinische Erfahrung und durch eine große Anzahl placebo-kontrollierter Studien eindeutig belegt ist, sind die Effekte dieser Substanzen auf den weiteren Krankheitsverlauf meistens weniger positiv. Zahlreiche Patienten sprechen nicht günstig auf die Medikation an oder verschlechtern sich sogar und viele Kranke erleben auch unter unterschiedlichen soziotherapeutischen Maßnahmen nur eine geringe Besserung ihres Befindens. Die Mehrzahl dieser Patienten weist sowohl positive und negative Symptome als auch schwerwiegende funktionelle Defizite und Verhaltensauffälligkeiten auf.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abbuzzahab FS, Zimmermann RL (1980) Factors determining patient tenure on a 3-year double-blind investigation of pimozide versus fluphenazine HCl. Adv Biochem Psychopharmacol 24: 547–550

    Google Scholar 

  • Addington J, Addington D (1991) Positive and negative symptoms of schizophrenia their course and relationship over time. Schizo Res 5: 51–59

    Article  CAS  Google Scholar 

  • Andersen K, D’Elia G, Hallberg B, Perris C, Rapp W, Roman G (1974) A controlled trial of pimozide and trifluoperazine and chronic schizophrenic syndromes. Acta Psychiatr Scand 50 [Suppl 24]: 43–64

    Article  Google Scholar 

  • Andreasen NC (ed) (1990) Schizophrenia: Positive and negative symptoms and syndromes. Mod Probl Pharmacopsychiatry, Vol 24. Karger, Basel

    Google Scholar 

  • Angrist B, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacology 72: 17–19

    Article  PubMed  CAS  Google Scholar 

  • Berner P (1984) Die Schizophreniebehandlung mit Dogmatil-Eifahrungen aus 15 Jahren. In: Benkert O (Hrsg) 15 Jahre Erfahrung mit Dogmatil®. Zuckschwerdt, München

    Google Scholar 

  • Boyer P, Lecrubier Y, Puech AJ (1990) Treatment of positive and negative symptoms: Pharmacologic approaches. In: Andreasen NC (ed) Schizophrenia: Positive and negative symptoms and syndromes. Mod Probl Pharmacopsychiatry, Vol 24. Karger, Basel, pp 152–174

    Google Scholar 

  • Breier A, Wolkowitz OM, Doran AR, Roy A, BoronowJ, Hommer DW, Pickar D (1987) Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 144: 1549–1555

    CAS  Google Scholar 

  • Breier A, Schreiber JL, DyerJ, Pickar D (1991) National Institute of Mental Health: Longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 48: 239–246

    Google Scholar 

  • Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377–384

    Article  PubMed  CAS  Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66–68

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 70–87

    PubMed  CAS  Google Scholar 

  • Deister A, Marneros A, Rohde A (1990) Zur Stabilität negativer und positiver Syndromatik. In: Möller HJ, Pelzer E (eds) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 25–34

    Chapter  Google Scholar 

  • De Leon J, Simpson GM (1991) Do schizophrenic negative symptoms respond to neuroleptics? Integr Psychiatry 7: 39–47

    Google Scholar 

  • Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatria 19: 134–139

    Article  CAS  Google Scholar 

  • Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi D (1980) Controlled trial of Sulpirid in chronic schizophrenic patients. Br J Psychiatry 137: 522–529

    Article  PubMed  CAS  Google Scholar 

  • Feinberg SS, Kay SR, Elijovich LR, Fiszbein A, Lewis A, Opler LA (1988) Pimozide treatment of the negative schizophrenic syndrome: an open trial. J Clin Psychiatry 49: 235–238

    PubMed  CAS  Google Scholar 

  • Gaebel W, Pietzcker A (1985) Multidimensional study of the outcome of schizophrenic patients 1 year elfter clinic discharge. Eur Arch Psychiatry Neurol Sci 235: 45–52

    Article  PubMed  CAS  Google Scholar 

  • Gaebel W, Pietzcker A, Ulrich G, Schley J, Müller-Oerlinghausen B (1988) Möglichkeiten der Voraussage des Erfolges einer Akutbehandlung mit Perazin anhand der Reaktion auf eine Perazintestdosis. In: Helmchen H, Hippius H, Tölle R (Hrsg) Therapie mit Neuroleptika — Perazin. Thieme, Stuttgart, S 159–172

    Google Scholar 

  • Gelders YG (1990) Die Bedeutung des 5-HT2-Rezeptor-Antagonismus für die Behandlung der Schizophrenie, unter spezieller Berücksichtigung der Minussymptomatik. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S 223–230

    Chapter  Google Scholar 

  • Gerlach J, Behnke K, Heltberg J, Munk-Andersen E, Nielsen H (1985) Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry 147: 283–288

    Article  PubMed  CAS  Google Scholar 

  • Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456

    PubMed  CAS  Google Scholar 

  • Haas S, Beckmann H (1982) Pimozide versus haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria 15: 70–74

    Google Scholar 

  • Härnryd C, Bjerkenstedt L, Björk K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA, Wik G, Aberg-Wistedt A (1984) Clinical evaluation of sulpiride in schizophrenic patients: A double-blind comparison with chlorpromazine. Acta Psychiatr Scand [Suppl] 311: 7–30

    Google Scholar 

  • Honigfeld G, Patin J, Singer J (1984) Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Therapy 1: 77–97

    Google Scholar 

  • Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet I: 848–851

    Google Scholar 

  • Johnstone EC, Owens DGC, Frith CD, Crow TJ (1986) The relative stability of positive and negative features in chronic schizophrenia. Br J Psychiatry 150: 60–64

    Article  Google Scholar 

  • Juul Povlsen U, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 71: 176–185

    Article  Google Scholar 

  • Kane JM, Mayerhoff D (1989) Do negative symptoms respond to pharmacological treatment? Br J Psychiatry 155 [Suppl 7]: 115–118

    Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meitzer H (1988) Clozapine for the treatment-resistant schizophrenic a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796

    Article  PubMed  CAS  Google Scholar 

  • Keefe RSE, Lobel DS, Mohs RC, Silverman JM, Harvey PD, Davidson M, Losonczy MF, Davis KL (1991) Diagnostic issues in chronic schizophrenia: Kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophr Res 4: 71–79

    Google Scholar 

  • Kolivakis T, Azim H, Kingstone E (1974) A double-blind comparison of pimozide and chlorpromazine in the mantenance care of chronic outpatients. Curr Ther Res 16: 998–1004

    PubMed  CAS  Google Scholar 

  • Kuha S, Miettinen E (1986) Long-term effect of clozapine in schizophrenia. Nord Psykiatr Tidsfkr 40: 225–230

    Article  Google Scholar 

  • Lieberman JA, Kane JM, Johns CA (1989) Clozapine: Guidelines for clinical management. J Clin Psychiatry 50: 329–338

    Google Scholar 

  • Lieberman JA, Jody D, Alvir JMJ, Borenstein M, Mayerhoff DI, Geisler S, Szymanski S, Gonzales A, Bogerts B, Ash tari M (1991) Negative symptoms in schizophrenia: relation¬ship to positive symptoms and outcome. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 109–125

    Google Scholar 

  • Lindström LH (1988) The effect of long-term treatment with clozapine in schizophrenia. Acta Psychiatr Scand 77: 524–529

    Article  PubMed  Google Scholar 

  • Marneros A, Andreasen NC, Tsuang MT (eds) (1991) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Maurer K, Hafner H (1991) Dependence, independence or interdependence of positive and negative symptoms. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 160–182

    Chapter  Google Scholar 

  • May PRA, Goldberg SC (1978) Prediction of schizophrenia. Patients’ response to pharmacotherapy. In: Lipton MA (ed) Psychopharmacology — a generation or progress. Raven, New York

    Google Scholar 

  • May PRA, Dencker SJ, Hubbard JW, Midha KK, Libermann RP (1988) Ein systematischer Ansatz zur Therapieresistenz schizophrener Erkrankungen. In: Bender W, Dencker SJ, Kulhanek F (Hrsg) Schizophrene Erkrankungen Therapie, Therapieresistenz — eine Standortbestimmung. Vieweg, Braunschweig, S 133–150

    Google Scholar 

  • Meltzer HY (1985) Dopamine and negative symptoms in schizophrenia: critique of the type I-type II hypothesis. In: Alpert M (ed) Controversies in schizophrenia: Changes and constancies. Guilford, New York, pp 110-136 Meitzer HY (1987) Effect of neuroleptics on the schizophrenic syndrome. In: Dahl SG, Gram LF, Potter P (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 255–265

    Google Scholar 

  • Meltzer HY (1991) The effect of clozapine and other atypical antipsychotic drugs in negative symptoms. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 365–375

    Chapter  Google Scholar 

  • Meitzer HY, Zureick J (1989) Negative symptoms in schizophrenia: a target for new drug development. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 68–77

    Google Scholar 

  • Möller HJ (1991) Typical neuroleptics in the treatment of positive and negative symptoms. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 341–364

    Google Scholar 

  • Möller HJ (1992) Neuroleptic treatement of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur J Psychopharmacology

    Google Scholar 

  • Möller HJ, Zerssen D von (1986) Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Möller HJ, Pelzer E (Hrsg) (1990) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Möller HJ, Kissling W, Zerssen D von (1983) Die prognostische Bedeutung des frühen Ansprechens schizophrener Patienten auf Neuroleptika für den weiteren stationären Behandlungsverlauf. Pharmacopsychiatria 16: 46–49

    Article  PubMed  Google Scholar 

  • Müller-Spahn F, Modell S, Thomma M (1992) Neue Aspekte in der Diagnostik, Pathogenese und Therapie schizophrener Minussymptomatik. Nervenarzt 63: 383–400

    Google Scholar 

  • Naber D, Leppig M, Grohmann R, Hippius H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients. Psychopharmacology 99: 73–76

    Article  Google Scholar 

  • Nedopil N, Rüther E (1981) Initial improvement as predictor of outcome of neuroleptic therapy. Pharmacopsychiatria 14: 205–207

    Article  PubMed  CAS  Google Scholar 

  • Opler LA, Feinberg SS (1991) The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 52: 221–233

    PubMed  CAS  Google Scholar 

  • Peselow ED, Stanley M (1982) Clinical trials of benzamides in psychiatry. Adv Biochem Psychopharmacol 35: 163–194

    PubMed  CAS  Google Scholar 

  • Petit M, Zann M, Lesieur P, Colonna L (1987) The effect of sulpiride on negative symptoms of schizophrenia. Br J Psychiatry 150: 270 - 271

    Article  PubMed  CAS  Google Scholar 

  • Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH (1992) Clinical and biologic response to clozapine in patiens with schizophrenia — crossover comparison with fluphenazine. Arch Gen Psychiatry 49: 345–353

    Article  PubMed  CAS  Google Scholar 

  • Pinder RM, Brogden RN, Sawyer PR, Speight T, Spencer R, Avery GS (1976) Pimozide a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 12: 1–40

    Article  PubMed  CAS  Google Scholar 

  • Rao VAR, Bailey J, Bishop M, Coppen A (1981) A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology 73: 77–80

    Article  PubMed  CAS  Google Scholar 

  • Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336

    PubMed  CAS  Google Scholar 

  • Schubart C, Krumm B, Biehl H, Maurer K, Jung E (1987) Factors influencing the course and outcome of symptomatology and social adjustment in first-onset schizophrenics. In: Häfner H, Gattaz WF, Janzarik W (eds) Search for the causes of schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 98–106

    Chapter  Google Scholar 

  • Schüssler G, Müller-Oerlinghausen B, Schmidt LG (1988) Vergleich einer höher dosierten Haioperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten. In: Helmchen H, Hippius H, Tölle R (Hrsg) Therapie mit Neuroleptika-Perazin. Thieme, Stuttgart, S 40–50

    Google Scholar 

  • Serban G, Siegel S, Gaffney M (1992) Response of negative symptoms of schizophrenia to neuroleptic treatment. J Clin Psychiatry 53: 229–234

    PubMed  CAS  Google Scholar 

  • Sieberns S (1986) Darstellung der Depotneuroleptika. In: Heinrich K, Sieberns S (Hrsg) Internationales Fluanxol-Depot-Kolloquium. pmi, Frankfurt, S 7–18

    Google Scholar 

  • Simpson GM, Wilson WH (1989) Strategies for treating non-responding schizophrenics. In: Schulz SC, Tamminga CA (eds) Schizophrenia scientific progress. Oxford University Press, New York Oxford, pp 351–357

    Google Scholar 

  • Strauss JS, Carpenter WT (1977) The prediction of outcome in schizophrenia III. Five-year outcome and its predictors. Arch Gen Psychiatry 34: 159–163

    Google Scholar 

  • Tegeler J (1987) Differentielle Indikationen der neuroleptischen Akutbehandlung Schizophrener. In: Pichot P, Möller HJ (Hrsg) Neuroleptika Rückschau 1952–1986. Künftige Entwicklungen. Springer, Berlin Heidelberg New York Tokyo, S 47–62

    Google Scholar 

  • Tegeler J (1993) Vorgehen bei Neuroleptika-Non-Respondern. In: Möller HJ (Hrsg) Therapie psychiatrischer Erkrankungen. Enke, Stuttgart, S 196–200

    Google Scholar 

  • Wiesel F-A, Farde L, Nordström A-L, Sedvall G (1990) Die Bedeutung der Dl- und D2-Dopaminrezeptor-Blockade für die antipsychotische Wirkung von Neuroleptika. Eine PET-Studie an schizophrenen Patienten. In: Müller-Oerlinghausen B, Möller HJ, Rüther E (Hrsg) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Tokyo, S 13–20

    Google Scholar 

  • Woggon B (1980) Veränderungen der psychopathologischen Symptomatik während 20 tägiger antidepressiver oder neuroleptischer Behandlung. Psychiatr Clin (Basel) 13: 150–164

    CAS  Google Scholar 

  • Woggon B (1983) Prognose der Psychopharmakotherapie. Enke, Stuttgart

    Google Scholar 

  • Woggon B (1990) Wirkprofile klassischer Neuroleptika und die Beeinflussung von Minussymptomatik. In: Möller HJ,Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin Heidelberg New York Tokyo, S199–205

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Klinik, Heinrich-Heine-Universität, Rheinische Landesklinik Düsseldorf, Bergische Landstraße 2, D-40605, Düsseldorf, Bundesrepublik Deutschland

    Priv.-Doz. Dr. med. J. Tegeler

Authors
  1. Priv.-Doz. Dr. med. J. Tegeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrischen Universitätsklinik und Poliklinik, Sigmund-Freud-Straße 25, D-53115, Bonn-Venusberg, Deutschland

    Hans-Jürgen Möller (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag/Wien

About this paper

Cite this paper

Tegeler, J. (1993). Die Bedeutung der verschiedenen Neuroleptikagruppen unter dem Aspekt von Neuroleptika-Nonresponse. In: Möller, HJ. (eds) Therapieresistenz unter Neuroleptikabehandlung. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9292-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9292-4_11

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82461-0

  • Online ISBN: 978-3-7091-9292-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation